Kventiax Sr

Quetiapine, the active ingredient in Kventiax Sr, is an atypical antipsychotic presented as an oral dosage form for oral use. It is prescribed for the management of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder, helping to balance neurotransmitter activity in affected patients through modulation of serotonin and dopamine pathways.

GNH USA supplies Kventiax Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets with reliable logistics and documentation support.

Quetiapine is an atypical antipsychotic that modulates neurotransmission in psychotic and mood disorders.

- Schizophrenia: reduces hallucinations, delusions and other psychotic symptoms, improving functional outcomes. - Bipolar disorder: stabilizes mood during manic and depressive phases, decreasing episode frequency. - Major depressive disorder (adjunct therapy): enhances response to standard antidepressants when added to the regimen. - Psychotic depression: alleviates psychotic features accompanying depressive episodes.

Quetiapine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to oral discomfort. - Constipation: infrequent bowel movements or hard stools. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements, especially of the face. - Agranulocytosis: severe reduction in white blood cells, increasing infection risk.

When prescribing quetiapine, clinicians should consider several safety precautions to minimize risks.

- Assess cardiovascular status: monitor blood pressure and heart rate, especially in patients prone to orthostatic hypotension. - Evaluate metabolic risk: screen for diabetes, lipid abnormalities, and weight changes before and during therapy. - Review psychiatric history: monitor for emergence of suicidal thoughts or worsening depression. - Consider hepatic and renal function: adjust use in patients with significant liver or kidney impairment. - Avoid abrupt discontinuation: taper dose gradually to reduce risk of withdrawal symptoms. - Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Quetiapine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels, risking toxicity. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine concentrations, diminishing efficacy. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: enhanced hypotensive effect when combined with quetiapine. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Antidepressants (e.g., SSRIs, SNRIs): potential for increased serotonergic activity and QT prolongation.